The potential value of integrated natriuretic peptide and echo-guided heart failure management by Maria Chiara Scali et al.
CARDIOVASCULAR 
ULTRASOUND
Scali et al. Cardiovascular Ultrasound 2014, 12:27
http://www.cardiovascularultrasound.com/content/12/1/27REVIEW Open AccessThe potential value of integrated natriuretic
peptide and echo-guided heart failure
management
Maria Chiara Scali*, Anca Simioniuc, Frank Lloyd Dini and Mario MarzilliAbstract
There is increasing interest in guiding Heart Failure (HF) therapy with Brain Natriuretic Peptide (BNP) or N-terminal
prohormone of Brain Natriuretic Peptide (NT-proBNP), with the goal of lowering concentrations of these markers
(and maintaining their suppression) as part of the therapeutic approach in HF. However, recent European Society of
Cardiology (ESC) and American Heart Association/ American College of Cardiology (AHA/ACC) guidelines did not
recommend biomarker-guided therapy in the management of HF patients. This has likely to do with the conceptual,
methodological, and practical limitations of the Natriuretic Peptides (NP)-based approach, including biological variability,
slow time-course, poor specificity, cost and venipuncture, as well as to the lack of conclusive scientific evidence
after 15 years of intensive scientific work and industry investment in the field. An increase in NP can be associated
with accumulation of extra-vascular lung water, which is a sign of impending acute heart failure. If this is the case,
an higher dose of loop diuretics will improve symptoms. However, if no lung congestion is present, diuretics will
show no benefit and even harm. It is only a combined clinical, bio-humoral (for instance with evaluation of renal
function) and echocardiographic assessment which may unmask the pathophysiological (and possibly therapeutic)
heterogeneity underlying the same clinical and NP picture. Increase in B-lines will trigger increase of loop diuretics
(or dialysis); the marked increase in mitral insufficiency (at baseline or during exercise) will lead to increase in vasodilators
and to consider mitral valve repair; the presence of substantial inotropic reserve during stress will give a substantially
higher chance of benefit to beta-blocker or Cardiac Resynchronization Therapy (CRT). To each patient its own therapy,
not with a “blind date” with symptoms and NP and carpet bombing with drugs, but with an open-eye targeted
approach on the mechanism predominant in that individual patient. A monocular, specialistic, unidimensional
approach to HF can miss its pathogenetic and clinical complexity, which only can be overcome with an integrated,
versatile and tailored approach.
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Approximately 5.1 million people > 20 years old in the
USA live with chronic Heart Failure (HF). An estimated
670,000 new cases are diagnosed annually among USA
adults > 45 years old, and HF causes or contributes to
almost 300,000 deaths each year. Various demographic
trends, including the aging of the population and greater
likelihood of survival after acute myocardial infarction,
suggest that the prevalence of HF will likely continue to* Correspondence: chiara_scali@yahoo.it
Unità Operativa Malattie Cardiovascolari 1, Dipartimento Cardio-Toracico e
Vascolare, Azienda Ospedaliera-Universitaria Pisana, Via Paradisa, 2. 56124
Pisa, Italy
© 2014 Scali et al.; licensee BioMed Central Lt
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.increase; indeed, the American Heart Association (AHA)
estimates that by 2030, HF prevalence will increase by
25% over 2013 estimates [1].
Although there have been significant advances in the
treatment of HF, morbidity and mortality remain high.
Pharmacologic regimens have become increasingly
complex, and standard therapy now often consists of
multiple drugs (angiotensin-converting enzyme inhibitors,
angiotensin receptor blockers, beta-blockers, aldosterone
antagonists, diuretics, digoxin, and, in African-American
patients, hydralazine and isosorbide dinitrate). The eco-
nomic impact is significant as well and costs of HF
hospitalizations amount to $29 billion/year in the USAd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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there is increasing interest in using cardiovascular bio-
markers for a personalized medicine approach to more
effectively guide diagnosis, risk stratification, and therapy
[2]. This review aims to provide a reassessment of patho-
physiological rationale and existing evidences, highlighting
the value and limitations of the currently employed clinical
approach based on Natriuretic Peptides (NP), and outline
the potential of an alternative, cardiovascular ultrasound-
based approach for personalized treatment of HF.
Biomarkers in HF therapy
In many disease states, drug selection and dosage are
strictly dependent from biomarkers [3]. Classic experience
with diabetes has taught clinicians to adjust hypoglycemic
agents dose to blood glucose levels. The idea of transfer-
ring a similar approach to HF may appear attractive.
Unfortunately, in HF some basic requirements for such
a transposition are missing. HF is a complex systemic
syndrome and HF symptoms do not have a consistent
relation with severity of Left Ventricular (LV) dysfunction,
but express malfunction of adaptive mechanisms, includ-
ing the natriuretic peptide system, the renin-angiotensin-
aldosterone system, and the autonomic nervous system.
There is no reason to believe that these systems have a
uniform behavior in different forms of HF. Conversely,
drug therapy of HF has assumed a uniform response to
treatment, irrespective of the pathogenetic mechanism.
Based on this oversimplification, HF from global dysfunc-
tion of the cardiac muscle, such as in dilated cardiomyop-
athy, is expected to receive the same treatment as HF
associated with regional wall dysfunction, such as in
ischemic cardiomyopathy, and even HF in patients with
valvular heart disease or hypertrophic cardiomyopathy.
Moreover, current guidelines do not consider adjustment
of drug selection and dosage to severity of HF symptoms.
All symptomatic patients are expected to receive all the
agents proven to be beneficial in Randomized Clinical
Trials (RCT), at the dosage prescribed in the RCTs, with
limited if any room to tailoring of therapy to patient’s
need.
Recognizing the heterogeneity of HF and dissecting it
into different therapeutic groups would improve the
targeting of interventions, which in turn could improve
response rates and avoid adverse effects in patients un-
likely to benefit. Studies have demonstrated the need to
target specific phenotypes based on this heterogeneity
[4]. Moreover accurate targeting of therapies could allow
the focused use of the drugs most likely to be effective
and safe in a given individual, thereby potentially enhan-
cing compliance, improving outcomes, and lowering the
cost of medical care. Based on these concepts, it appears
that the limitations of current approaches in guiding HF
therapy express more the limitations of our understandingof the pathogenesis of these conditions and the simpli-
fications of current therapeutic approach, than intrinsic
inadequacy of the employed biomarkers. Heterogeneity
in response to therapies warrants further research to
identify biomarkers that can not only stratify risk but
also identify the underlying disease process that may be
targeted by specific therapies.
Biology of NP in HF
Circulating levels of NP are normally very low in healthy
individuals. In response to increased myocardial wall stress
due to volume- or pressure-overload states (such as in HF),
the Brain Natriuretic Peptide (BNP) gene is activated in
cardiomyocytes. This results in the production of an
intracellular precursor propeptide (proBNP108); further
processing of this propeptide results in release of the
biologically inert aminoterminal fragment called N-terminal
prohormone of Brain Natriuretic Peptide (NT-proBNP)and
the biologically active BNP [5]. In addition, a significant
portion of BNP or NT-proBNP detected by current assays
includes uncleaved proBNP108, whereas BNP concentra-
tions also include the detection of various subfragments
that arise from the degradation of the intact BNP hormone.
The biological activity of BNP includes stimulation of
natriuresis and vasorelaxation; inhibition of renin, aldos-
terone, and sympathetic nervous activity; inhibition of
fibrosis; and improvement in myocardial relaxation.
Although released in a 1:1 ratio, the measured NT-proBNP
level is higher than that of BNP, in part because NT-
proBNP is passively cleared from the circulation more
slowly (half-life of 120 versus 20 minutes). Unlike BNP,
NT-proBNP is not cleared by NP receptors or neutral
endopeptidases. Rather, NT-proBNP is cleared by various
organs, including the skeletal tissue, liver, and kidneys.
A common misconception is that NT-proBNP is more
dependent on renal function for clearance than is BNP;
both are equally cleared by the kidneys.
BNP and NT-proBNP levels are increased in HF, and
correlate well with ventricular wall stress and severity of
HF. The Breathing Not Properly Multinational Study and
the Pro-BNP Investigation of Dyspnea in the Emergency
Department showed that NP levels were more accurate
for diagnosis or exclusion of Acute Decompensated Heart
Failure (ADHF) than clinical judgment, particularly in
the context of diagnostic uncertainty. When added to
comprehensive clinical assessment, BNP and NT-proBNP
are both incrementally useful for diagnosis of ADHF, and
both are endorsed in current practice guidelines for HF
evaluation (particularly when diagnostic indecision is
present). Elevated BNP (above approximately 125 pg/mL)
or NT-proBNP (above approximately 1000 pg/mL) values
are prognostically meaningful in chronic HF, and a rising
pattern is predictive of impending adverse outcome,
irrespective of other subjective and objective prognostic
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chronic HF (such as beta-blockers, vasodilators, or aldos-
terone blockers) tend to lower concentrations of BNP or
NT-proBNP.
Thus, there is increasing interest in guiding HF therapy
with BNP or NT-proBNP, with the goal of lowering
concentrations of these markers (and maintaining their
suppression) as part of the therapeutic approach in HF.
However, recent European Society of Cardiology (ESC)
and AHA/American College of Cardiology (ACC) guide-
lines [6,7] did not recommend biomarker-guided therapy
in the management of HF patients. Therefore, in contrast
to oncology, biomarker approaches are not yet routinely
used in the management of HF. This has likely to do with
the conceptual, methodological, and practical limitations
of the NP-based approach, as well as to the lack of conclu-
sive scientific evidence after 15 years of intensive scientific
work and industry investment in the field.
Limitations of NP approach
Limitations of NP-based approach include major limita-
tions (including biological variability, slow time-course,
poor specificity and lack of conclusive scientific evidences)
and minor weaknesses - such as cost and venipuncture.
Biological variability
The term “biological variability” refers to the extent of
changes of a biomarker in a stable physiological state. In
practice, biological variability indicates the change in
measurement that have a biological significance. Both
BNP and NT-proBNP are limited in their clinical use by
an excess variability that reaches 40% for BNP and 25%
for NT-proBNP [8]. Given a threshold of 1000 pg/mL
for the BNP-based diagnosis of cardiac origin of dyspnea,
this variability implies that measurements from 600 pg/mL
to 1400 pg/ml are biologically equivalent. The negative
implications of such variations are obvious in the follow-
up of HF patients. For NT-proBNP, the clinical variability
is less wide, but still clinically relevant around 25%. In the
real world this makes difficult or impossible to estimate if
changes BNP plasma levels that remain within this wide
range express real changes of patient conditions or only
spontaneous biological variability. Trials have used a
fixed [9-15] or individualized [16-18] NP target, with
no clear difference in results. Six trials testing the value
of NT-proBNP used target values ranging from 4000 to
2200 mg/L, with greater benefit observed with higher
target values, suggesting that the more aggressive efforts
to reduce NP values are not necessarily better.
Time course of BNP changes in response to therapy
Ideally, a biomarker should reflect as quickly as possible
improvement or worsening of patients’ conditions, either
spontaneous or therapy-induced. A fast response is evenmore essential in critical conditions such as decompen-
sated HF. Unfortunately, data from studies of serial
BNP measurements suggest that concentrations of NT-
proBNP require from 2 to 4 weeks after a therapy change
to stabilize [19]. Obviously this makes impossible to rely
on these measurements in unstable conditions.
Poor specificity
Most cardiologists believe that BNP and NT-proBNP dir-
ectly reflects variations in volume of cardiac chambers. This
is certainly true, but by no means a specific finding. In fact,
BNP and NT-proBNP levels change also in response to
arrhythmias, myocardial ischemia, valvular heart disease,
changes of filling pressures, diastolic function, only to
mention cardiac factors. Also non-cardiac factors, includ-
ing age, sex, body mass index and genetic factors are
important confounders, as are pulmonary hypertension,
pulmonary embolism and chronic kidney disease [20]. NP
levels correlate imperfectly with measured filling pressures
and may remain elevated in the absence of significant
congestion. Some drugs, such as beta-blockers, may in-
crease Ejection Fraction (EF) and improve prognosis, but
also increase NP levels through direct pharmacological
mechanisms unrelated to effects pump function [21]. Not
all causes that elevate NP values are cardiac in origin, and
in addition not all cardiac causes of elevation of NP relate
to increase in LV pressures and/or volumes. In this era of
progressively aging of the HF populations and growing
prevalence of comorbidities, the specificity and hence the
diagnostic value of NP is strongly challenged.
Lack of conclusive scientific evidence
In the era of evidence based medicine, no guideline can
be proposed if not supported by sound data. More than
9 trials have been completed and published since when
NP levels have been proposed to guide HF therapy.
The natriuretic peptide guided- strategy is associated
with reduction in all-couse mortality and HF- related
hospitalization as well as with the risk of readmission
for HF worsening, as shown by recent meta-analyses.
However further evidence is still needed to support a
more general use of NP, since the results of this trial
are inconclusive as regards cardiac death [22,23].
The results of these trials are inconsistent and incon-
clusive. The clear demonstration of this statement is that
an additional trial is being conducted and eagerly waited
by both supporters and skeptics (Guiding evidence based
therapy using biomarkers intensified treatment, GUIDE-
IT). The mixed results are after all not so surprising in
the light of previous limitations. NP increase is determined
by a spectrum of different pathophysiological conditions
(from lung congestion to systolic dysfunction to increase
of mitral insufficiency during exercise) and triggers a
monotonous therapeutic response, of questionable benefit
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relative increase in the use of angiotensin-enzyme inhibi-
tors, beta-blockers, angiotensin receptor blockers, and
spironolactone over standard, symptom-guided care. If
the physician relies on NP levels to assess volume status,
the choice of dose escalation of loop diuretics in patients
without pulmonary congestion may increase the rate of
hypotension, renal dysfunction and adverse outcome.
Cost
HF poses a heavy economic burden on western economies,
being one of the largest contributors to health cost. NP
measurements, though not very expensive add to the over-
all cost of HF therapy. The additional cost for each BNP
measurement varies largely from hospital to hospital, and
averages 30 €. NT-proBNP measurement is generally more
expensive. Given the need for serial measurements and the
number of the HF populations, it is easy to estimate how
much a systematic NP based approach would impact
on health cost. That is why a generalized use of NP
based therapy is not justified until conclusive evidence
is provided of its cost-effectiveness.
Need for venipuncture
This may appear as a minor nuisance for doctor and
patients, but sometimes the blood sampling may be a
challenging task in elderly, fragile, obese patients.
Based on the concepts expressed in preceding para-
graphs, therapy of HF might be reconsidered. An effort
should be made to identify the agents and the dosages to
be prescribed to patients according to the etiology of the
HF and to the severity of symptoms, abandoning the
current strategy of giving all agents, at the highest tested
dose, to all patients. It is conceivable that in this context,
patients can be identified in whom NP dosage may provide
a good guidance to therapy, and patients that do not have
benefit from such approach. This hypothesis would become
even more appealing if biomarkers with less biological
variability, greater specificity and faster time response
can become available.
The potential role of echocardiographic biomarkers in
heart failure
Echocardiography-derived parameters can fulfill the defin-
ition of biomarkers since in 2001, a working group of the
National Institutes of Health standardized the definition
of a biomarker as a “characteristic that is objectively mea-
sured and established as an indicator of normal biological
pathologic processes, pathogenetic processes, or pharma-
cologic responses to a therapeutic intervention”. A bio-
marker may be measured on a biosample (such as a blood
test, for instance, the D-dimer as a biomaker of vulnerable
blood) or it may be an imaging test (for instance, echocar-
diogram for vulnerable myocardium) [24].The ideal candidate biomarker should fulfill some basic
pre-requisites: 1) easily defined, safe, and reproducible in
each patient; 2) appropriate therapeutic counter measures
should be available to reset the abnormal biomarker
values towards normal range; 3) the biomarker-triggered
therapy change should improve outcome; 4) the biomarker-
driven approach should provide an improved benefit and
cost-benefit over standard approach.
A classical example of a powerful risk marker unsuitable
as a therapeutic target is serum sodium concentration.
The lower the sodium concentration, the higher the degree
of neuro-hormonal activation and the poorer the prognosis,
but treatment aimed at normalizing sodium levels will not
improve clinical outcomes [25].
Echo biomarkers in HF show several prerequisites for
being useful. According to the recent ESC guidelines on
HF, echocardiography is the imaging method of choice
for reasons of accuracy, availability (including port-
ability), safety and cost. The more frequently used echo
parameters are reported in Table 1. They are certainly
simple to measure, even with pocket-size instruments,
and reasonably reproducible in expert hands. They are
associated with strong prognostic power, and several
have shown independent and incremental prognostic
value over standard clinical and bio-humoral predictors.
They explore different and complementary aspects of
HF pathophysiology including: LV function (usually
with EF with biplane Simpson method, or with more
accurate but also more costly and technically demanding
Real Time 3D); right ventricular function (with tricuspid
annular plane systolic excursion); diastolic function (with
left atrial volume index, E/e’ ratio, E wave deceleration
time); extravascular lung water (exploring pulmonary con-
gestion with lung B-lines); mitral-insufficiency; pulmonary
hypertension (with pulmonary artery systolic pressure).
Another extremely attractive field is the assessment of
the behavior of these markers during exercise. Stress
echo applications beyond coronary artery disease are
emerging as an attractive field, and there is no question
that a moderate mitral insufficiency becoming severe
during stress and accompanied by B-lines and pulmonary
hypertension can make a mitral valve repair an attractive
therapeutic option. However, also in these cases the
evidences on points 3 and 4 on the chain of biomarker
validation are conspicuously lacking to date.Limitations of echocardiographic approach
In spite of the unsurpassed appeal in terms of low cost,
widespread access, versatility of the information provided,
there are limitations of echo-based approach, including de-
pendence on patient’s acoustic window, operator’s expertise
and lack of sufficient evidence based-data in echo-driven
management of HF patients [6].
Table 1 Common echocardiographic and lung sonography abnormalities in patients with heart failure
Measurement Abnormality Clinical implications
Parameters related to systolic function
LV ejection fraction Reduced (<50%) LV global systolic dysfunction
RV Tapse Reduced (<16 mm) RV global systolic dysfunction
Parameters related to diastolic function
E/e’ ratio Increased (>15) High LV filling pressure
Parameters related to pulmonary congestion
B-lines > 5 in anterior chest scan Extravascular lung water
Parameters related to valvular function
Mitral valve dysfunction Severe mitral regurgitation Cause/consequences of HF
Parameters related to contractile reserve
Global LV function during stress No contractile reserve Unresponsive scar tissue
LV, left ventricle; RV, right ventricle; TAPSE, tricuspid annular plane systolic excursion. Adapted from ESC 2012, ref 17.
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Although last generation echocardiographic instruments
allow satisfactory to excellent imaging in > 90% of patients
referred to echocardiography lab, poor acoustic windows
exist in a significant portion of subjects, for instance with
morbid obesity or lung disease. The use of intravenous
contrast agents for endocardial border enhancement
and better left ventricular cavity recognition is indicated
whenever ≥2 contiguous segments are not adequately
visualized [26] and considerably increases the success
rate of echocardiographic imaging, but with an extra cost.
In practical terms this implies that out of 10 patients
candidate for enrollment in an HF trial using an echo-
biomarkers only 8 to 9 can be considered eligible for
presence of good quality of echocardiograms allowing to
have not only interpretable but also measurable tracings.
Dependence on operator’s expertise
The echocardiographic examination is highly dependent on
the quality of image acquisition and analysis. Therefore,
strict criteria of image acquisition, storage and analysis are
required when echocardiographic data are used in a clinical
trial. The American Society of Echocardiography issued
some recommendations on these aspects, suggesting that
only certified and trained sonographers are involved in data
acquisition, and in multicenter trials core lab reading
by experinced operators blinded to patient identity and
study condition is recommended [27]. In addition, when-
ever possible a quantitative approach to image analysis
should be used. In fact, several quantitative approaches
have been recently proposed to evaluate ultrosound
biomarkers with an operator-independent, quantitative
approach for instance to assess left ventricular function
with 2D speckle tracking technology [28] This will
increase the precision of the method and reduce the
sample size required to achieve the required statistical
power of a trial [27].Lack of sufficient outcome data
Although a large number of observational studies support
the use and prognostic values of several echocardiographic
markers of HF, we still miss prospective randomized trials
based on echo parameters as a guide to treatment. When
this has been done in other fields, results have not been
always in line with the expectation and conventional
wisdom. For instance PROSPECT study did not confirm
that mechanical dyssynchrony with echo is associated
to better outcome with CRT therapy [29]; COURAGE did
not show that ischemia-driven revascularization improves
prognosis over optimal medical therapy in patients with
stable angina [30]; and STICH trial did not show that
myocardial viability is associated to better prognosis in
revascularized subjects with left ventricular dysfunction
over medically treated patients [31].
It is obvious at this point that we need stronger evidence
from prospective randomized outcome data before we can
use echocardiography to guide our therapy choices in
heart failure.
Conclusion
An integrated ultrasound assessment with echocardio-
graphic and lung ultrasound, in resting conditions and
even better during stress [32], can provide a spectrum of
pathophysiological and hemodynamic information, which
can conceivably be mirrored in selective, personalized,
tailored therapeutic decisions (Figure 1).
The concept of the application of biomarkers as a
guide to therapy is certainly an interesting one, which has
stood the test of time. Not all HF patients with the same
clinical picture were created equal, and NP assessment
identifies higher and lower risk subgroups, which may
help in guiding a different level of treatment intensity. We
have learned in the past 15 years that the good clinician
needs little help in starting an appropriate therapy of HF


























Figure 1 From natriuretic peptide driven (without imaging support) to “echo-print” individualized and tailored treatment in heart failure:
different echocardiographic fingerprints (“echo-print”) have different therapeutic implications. For instance, evidence of pulmonary congestion
(right upper panel) through B-lines supports the use of diuretic treatment, whereas the lack of contractile reserve during dobutamine stress echo (right
lower panel) discourages the indication to CRT.
Table 2 Biomarkers in heart failure
What we have What we need
Clinical presentation Physical
exam + chemistry
Safe and low cost
Imaging
Biomarkers Natriuretic peptides Echo-print




Proof of concept Proof of efficacy
Scali et al. Cardiovascular Ultrasound 2014, 12:27 Page 6 of 8
http://www.cardiovascularultrasound.com/content/12/1/27the best therapy in the HF patient to prevent acute
decompensation or catastrophic complications. Many
attempts in these directions including the simple NP-
guided therapy met only limited success with uncertain
impact on mortality. On the light of the evidences pre-
sented, this cannot be considered surprising since the
increase in NP is a monotonous response to a variety of
different patho-physiological input conditions and, fur-
thermore, it evokes a rather monotone output response
with intensification of drug treatment. This simple and
straightforward diagnostic and therapeutic algorithm
can be beneficial in some patients, neutral in others,
and detrimental in a subset. For instance, an increase in
NP can be associated with accumulation of extra-vascular
lung water, which is a sign of impending acute heart
failure. If this is the case, an higher dose of loop diuretics
will improve symptoms. However, if no lung congestion is
present, diuretics will show no benefit and even harm.
It is only a combined clinical, bio-humoral (for instance
with evaluation of renal function) and echocardiographic
assessment which may unmask the pathophysiological
(and possibly therapeutic) heterogeneity underlying the
same clinical and NP picture. Increase in B-lines will
trigger increase of loop diuretics (or dialysis); the marked
increase in mitral insufficiency (at baseline or during exer-
cise) will lead to increase in vasodilators and to consider
mitral valve repair; the presence of substantial inotropic
reserve during stress will give a substantially higher
chance of benefit to beta-blocker or CRT therapy [33-35].
To each patient its own therapy, not with a “blind date”
with symptoms and NP and carpet bombing with drugs,
but with an open-eye targeted approach on the mechan-
ism predominant in that individual patient. A monocular,
specialistic, unidimensional approach to HF can miss its
pathogenetic and clinical complexity, which only can beovercome with an integrated, versatile and tailored ap-
proach. This is a rational clinical strategy today, but it is
also a roadmap for future research, which should promote
outcome studies with echo-driven therapy compared with
the standard approach. At least one large-scale, prospect-
ive, randomized trial is already in progress in high-risk
chronic kidney disease patients with heart failure and
renal insufficiency and on dialysis—the LUST Trial (Lung
water by UltraSound guided Treatment to prevent death
and cardiovascular complications in high-risk end-stage
renal disease patients with cardiomyopathy) [36]. The re-
sults of this study will be crucial eventually to incorporate
B-lines into our clinically oriented diagnostic algorithms.
Another single-center trial comparing the outcome of B-
lines driven therapy versus standard therapy in ambula-
tory outpatients is ongoing [37]. At this point, the stage is
set for prospective trials comparing outcome in standard
(or NP-based) [38] versus echo-driven tailored therapy of
HF, moving from a blind, bio-humoral, one-fits-all ap-
proach to an open-eye, imaging-guided, therapeutically
versatile approach to the patient with HF. In the manage-
ment of HP patient, even the best cardiologist needs help
– but the help provided by NP is costly, pathophysiologic-
ally ambiguous, with clear additional economic burden
and unclear benefit of outcome. The “peptide-diuretic
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reflex of an anatomy-driven coronary revascularization.
We need a better way to titrate and personalize therapy
in our HF patient (Table 2). It is up to the cardiology
and echocardiography community to build the missing
evidence required to shift the practice of HF from art of
clinicians to evidence- based tailored and individualized
treatment of HF guided by low cost portable radiation-
free imaging techniques [39,40].
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